Post-concussion syndrome

TheraSpecs® Announces Groundbreaking New Product Lines to Tackle Brain Injuries, Epilepsy, and More

Retrieved on: 
Thursday, December 7, 2023
Brain, Sleep, Migraine, Research, Catalog, Lens, Photosensitive epilepsy, Headache, Concussion, Multimedia, Light, Health, Seizure, Photophobia, GLARE, Epilepsy, Insomnia, Flex, Post-concussion syndrome, Telescopic sight, Camera, PHOENIX

PHOENIX, Dec. 7, 2023 /PRNewswire-PRWeb/ -- TheraSpecs® Company, the leading brand of therapeutically tinted glasses for migraine and light sensitivity, today announced multiple new product lines designed for a wide range of additional symptoms, conditions, and situations. As the first company to offer such a line direct to consumers, TheraSpecs is positioned to help millions with brain injuries, photosensitive epilepsy, insomnia, and computer headaches.

Key Points: 
  • As the first company to offer such a line direct to consumers, TheraSpecs is positioned to help millions with brain injuries, photosensitive epilepsy, insomnia, and computer headaches.
  • "I started TheraSpecs in 2011 to help my wife and people like her with debilitating chronic migraine," said founder and CEO, Hart Shafer.
  • They've been made even better with the addition of premium optical coatings that further reduce scratches, smudges, and glare.
  • These are hands down the best product I have ever invested in and my overall health and well-being has been positively impacted!"

Neuronic Welcomes Light Therapy Experts to its Scientific Advisory Board

Retrieved on: 
Thursday, August 31, 2023
Lymphedema, University, Delirium, Coronavirus Scientific Advisory Board, Human, Research, Nanomedicine, Brain, Federation of European Pharmacological Societies, Inflammation, Biomarker, Associate, Bachelor of Science, World Association for Medical Law, BPS, Harvard Medical School, CTE, Low-level laser therapy, Alzheimer's disease, Parkinson's disease, Publication, ARCS, COVID-19, Tissue engineering, Laser, Pain management, PBM, Allied health professions, EGG, British Pharmacological Society, WALT, Post-concussion syndrome, University of Johannesburg, Chronic pain, ALS, Distinguishing, Durham University, Pharmaceutical industry, Nursing, Cholinergic neuron, Honours degree, Dermatology, Doctor of Philosophy, Medicine

EGG HARBOR, N.J, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Neuronic, a pioneering company in the field of photobiomodulation (PBM) technology, also known as light therapy, is proud to announce the addition of three distinguished individuals to its Scientific Advisory Board.

Key Points: 
  • EGG HARBOR, N.J, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Neuronic , a pioneering company in the field of photobiomodulation (PBM) technology, also known as light therapy, is proud to announce the addition of three distinguished individuals to its Scientific Advisory Board.
  • These esteemed individuals, collectively joining Neuronic's Scientific Advisory Board , underscore the company's commitment to advancing the frontiers of photobiomodulation.
  • "Our new Scientific Advisory Board members symbolize the excellence and innovation we strive for at Neuronic," said Liam Pingree , co-founder of Neuronic.
  • "We are thrilled to welcome these distinguished experts who share our vision and passion for enhancing brain wellness through photobiomodulation."

NeurAxis Highlights Pediatric Post-Concussion Clinical Study

Retrieved on: 
Tuesday, August 29, 2023
Neuraxis, Headache, Post-concussion syndrome, Effect, Orange County, Research, Abdominal pain, Literature, Dizziness, Patient, IBS, PCS, Sport, Nausea, Immediate, FDA, Concussion, NYSE, Pharmaceutical industry

Brian Carrico, President and Chief Executive Officer of NeurAxis, said, “We are thrilled to support this research because if the data is positive and the FDA gives clearance, this would be a groundbreaking therapeutic option for post-concussion syndrome.

Key Points: 
  • Brian Carrico, President and Chief Executive Officer of NeurAxis, said, “We are thrilled to support this research because if the data is positive and the FDA gives clearance, this would be a groundbreaking therapeutic option for post-concussion syndrome.
  • According to literature, the majority of concussions occur in children, mainly due to sports and unstructured play with or without helmets.
  • While symptoms generally resolve in a few weeks, others persist, including ongoing headaches, nausea, and dizziness, as well as mood and behavioral disorders.
  • Currently enrolling up to 100 patients, the clinical trial’s primary endpoint is improvements in validated measures, including the Immediate Post-Concussion Assessment, Post-Concussion Symptom Scale, and Balance Error Scoring Symptom compared to placebo.

New study highlights the brain trauma risks for young athletes

Retrieved on: 
Tuesday, August 29, 2023
People, Concussion, Football, Australian Sports Brain Bank, Senate, Prevalence, Life, DSM-IV codes, AFLW, Suicide, Boston University CTE Center and Brain Bank, Pathology, Fear, Dementia, Injury, Woman, NRL, Brain, Research, Risk, Boston University, National Rugby League, CTE, Athlete, Chronic traumatic encephalopathy, Public health, United States Soccer Federation, Sport, United Kingdom, Diagnosis, Health, Post-concussion syndrome, Trauma, Courage, AFL, Female, Soccer World Cup at the 2001 CPISRA World Games, Disease, Borosilicate glass, Medical imaging, Personal protective equipment, Sports equipment

The Boston University CTE Center today reported the results of the largest-ever study of chronic traumatic encephalopathy (CTE) in young athletes.

Key Points: 
  • The Boston University CTE Center today reported the results of the largest-ever study of chronic traumatic encephalopathy (CTE) in young athletes.
  • The study, examining autopsied tissue, found signs of CTE in 63 out of 152 young athlete brains.
  • The subjects of the study competed in youth, high school and college competitions, and all died before the age of 30.

CTE and young athletes

    • However, some high-profile cases of CTE have been identified among younger athletes.
    • In Australia, much-loved NRL player and coach Paul Green was 49 when he died and was later found to have CTE.
    • The risk factors for young athletes are complex and multifaceted but it is likely that playing junior contact sport heightens an athlete’s risk of developing neurodegenerative diseases as an adult.
    • For the athletes in the Boston University study to develop CTE before the age of 30, it is likely they were exposed to repeated brain trauma from an early age through youth sport.

Are contact sports safe for kids?

    • Public health advocates in North America, Australia, New Zealand Aotearoa and the United Kingdom have long expressed concerns about the risks of contact sport for children.
    • Improved oversight would go some way toward reducing the serious health risks of mild traumatic brain injury (concussion).

First steps

    • To protect them from the disease, contact sporting bodies must reduce young athletes’ lifetime exposure to brain trauma.
    • One way to do this would be to restrict contact in training and games for juniors.
    • Some sporting bodies have already taken the initial steps.
    • Australian Rules football players are restricted to modified tackling until the age of 12.
    • The National Rugby League will soon implement a ban on tackling until midway through under-7s competitions.

NeurAxis Announces Over $8 Million in IB-Stim™ Revenue

Retrieved on: 
Thursday, August 17, 2023
Neuraxis, IPO, Irritable bowel syndrome, Risk, Abdominal pain, Movement, Vomiting, Patient, Cyclic vomiting syndrome, Nausea, Security (finance), Post-concussion syndrome, FDA, NYSE, Pharmaceutical industry

Sales began after NeurAxis received FDA clearance for IB-Stim™ in the pediatric treatment of functional abdominal pain and irritable bowel syndrome.

Key Points: 
  • Sales began after NeurAxis received FDA clearance for IB-Stim™ in the pediatric treatment of functional abdominal pain and irritable bowel syndrome.
  • NeurAxis is conducting clinical trials with IB-Stim™ for four additional pediatric indications, including chronic nausea, post-concussion syndrome, chemotherapy induced nausea and vomiting, and cyclic vomiting syndrome.
  • Approximately $2 million of the over $8 million in IB-Stim™ revenue through March 31, 2023 was generated in 2020 and 2019.
  • You should, however, consult further disclosures and risk factors we include in our filings with the Securities and Exchange Commission.

Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update

Retrieved on: 
Tuesday, August 8, 2023
Marketing, Stanford University, Electromagnetic hypersensitivity, Patient, Concussion, Stroke, Columbia University, NFL, Telehealth, Headache, Therapy, Defense, OTCQB, Research, TBI, Attention, Veteran, Athlete, Dementia, Growth, FDA, Post-concussion syndrome, Deficit spending, Multiple sclerosis, Compound annual growth rate, Dizziness, PCS, Partnership, PEMF, Traumatic brain injury, Veterans Health Administration, Quality of life, Inflammation, CNS, Disorder, Central nervous system, Management, Pharmaceutical industry, Weisberg

The strategic hiring of Weisberg to lead sales, marketing and brand initiatives is set to drive Endonovo's expansion and distribution efforts.

Key Points: 
  • The strategic hiring of Weisberg to lead sales, marketing and brand initiatives is set to drive Endonovo's expansion and distribution efforts.
  • The Company's innovative approach to pain relief and non-opioid alternatives has garnered widespread attention in expanding medical markets.
  • In the first quarter of 2023, we solidified a strategic partnership with Academy Medical, a leading distribution company, serving Veterans and Dept of Defense patients.
  • The agreement can help to play a pivotal role in delivering essential PEMF- therapies and medical products to government facilities.

First-Ever BioMech Clinical Motion Lab Opens in Atlanta to Accelerate Traumatically Injured Patients' Recovery using AI-driven Motion Science Technology in Clinic and at Home

Retrieved on: 
Wednesday, August 2, 2023
Palisade, Golden West Pace, Gait, Ligament, Intelligence, Skull, Chiropractic, Movement, Military personnel, INC, Neuropsychiatry, Injury, Mevalonate pathway, Patient, Physician, Personality, Post-concussion syndrome, Neurology, Memory, Nursing, Medical imaging

RICHMOND, Va., Aug. 2, 2023 /PRNewswire/ -- BioMech Health, LLC, a division of BioMech Holdings, LLC, announced that Atlanta-based Independent Neurodiagnostic Clinic (INC) and BioMech have partnered to deliver state-of-the-art clinical motion analytics to advance patient treatment. The groundbreaking motion lab allows physicians to quantitatively measure and monitor patients' pre-and post-treatment function to determine appropriate treatment and assess progress to improve recovery. The system also provides real-time biofeedback to assist recovery, anytime, anywhere.

Key Points: 
  • The groundbreaking motion lab allows physicians to quantitatively measure and monitor patients' pre-and post-treatment function to determine appropriate treatment and assess progress to improve recovery.
  • The BioMech Clinical Motion Lab located at the Palisades at West Paces in Atlanta, Georgia, provides access to critical services such as neurology, neuropsychiatry, speech pathology, physiatry, and orthopaedics/spine.
  • This multispecialty motion lab is focused on helping patients by restoring function during the treatment process.
  • "It is a key differentiator of the BioMech system, and why the BioMech Clinical Lab should be part of every neurology, orthopaedic and physiatry clinic."

Aviv Clinics Highlights New Literature Review Sharing the Efficacy of Hyperbaric Oxygen Therapy for Traumatic Brain Injury Patients

Retrieved on: 
Tuesday, August 1, 2023
Survivor, University, HBOT, Oxygen, Stroke, Cohort (statistics), Neurology, Quality of life, Research, Brain, TBI, COVID, Meta-analysis, Brain damage, Science, National Association Medical Staff Services, Literature, Journal of the Royal Society of Medicine, University of Pittsburgh Medical Center, Patient, Traumatic brain injury, Shamir Medical Center, Mortality, Post-concussion syndrome, Health, PTSD, Hyperbaric medicine, PPCS, Medical device, Aviv, Tel Aviv University

ORLANDO, Fla., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Aviv Clinics , one of the most advanced brain clinics in the world, shares the results of a new comprehensive literature review that shows hyperbaric oxygen therapy (HBOT) should be recommended as an effective therapy for patients suffering with chronic mild traumatic brain injury (TBI).

Key Points: 
  • ORLANDO, Fla., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Aviv Clinics , one of the most advanced brain clinics in the world, shares the results of a new comprehensive literature review that shows hyperbaric oxygen therapy (HBOT) should be recommended as an effective therapy for patients suffering with chronic mild traumatic brain injury (TBI).
  • Chronic mild traumatic brain injury occurs when symptoms from a mild traumatic brain injury are prolonged and last for more than six months.
  • The literature review, The efficacy of hyperbaric oxygen therapy in traumatic brain injury patients: literature review and clinical guidelines, was conducted by the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, Tel Aviv University and University of Pittsburgh Medical Center’s neurosurgery department , and published in the official journal of the European Society of Medicine, Medical Research Archives .
  • Many people are dealing with symptoms of chronic traumatic brain injury, and the current rehabilitation methods are limited in their efficacy.

New Study by GWU Professor Reveals Breakthrough “Brain Fitness Program” for Patients with ADHD, Concussion, and Memory Loss

Retrieved on: 
Thursday, June 29, 2023
Neurology, Mental Health, Health, Science, Research, Exercise, Learning, Concussion, Function (mathematics), Depression, Diet, Interview, Alertness, Subjective, Verbal memory, Psychology, Sleep, ADHD, Deficit spending, Quality of life, Hope, Brain, Attention, Doctor of Philosophy, Journal, Attention deficit hyperactivity disorder, Patient, EEG, PCS, Amnesia, Biology, Johns Hopkins, Post-concussion syndrome, George Washington University, Memory, Pharmaceutical industry, Medical imaging, Dietary supplement, Medical device, Rehabilitation, MD

“The program's emphasis on improving neuroplasticity through non-drug interventions holds great potential for people who suffer from poor attention, persistent concussion symptoms, or memory loss.

Key Points: 
  • “The program's emphasis on improving neuroplasticity through non-drug interventions holds great potential for people who suffer from poor attention, persistent concussion symptoms, or memory loss.
  • The cohort encompassed 71 individuals with ADHD, 88 with PCS, and 64 with memory loss (Mild Cognitive Impairment or Subjective Cognitive Decline).
  • The study follows earlier research findings by Dr. Fotuhi that these interventions are effective for patients with memory loss or traumatic brain injury.
  • For additional information about the study or to schedule an interview with Dr. Fotuhi, contact Shawn Flaherty at 703-554-3609.

BRAINBox Solutions to Present HeadSMART II Trial Demographic, Clinical Trends Data at Two Upcoming Medical Meetings

Retrieved on: 
Thursday, May 4, 2023
SAB, Concussion, Society, Emergency medicine, Academic Emergency Medicine, Virginia Tech Carilion School of Medicine and Research Institute, Urgent care center, Post-concussion syndrome, Traumatic brain injury, Baylor University, Coronavirus Scientific Advisory Board, TBI, Trauma center, Society for Academic Emergency Medicine, MD, Patient, Algorithm, Baylor College of Medicine, Diagnosis, Research, FDA, Trauma, Conference, NIH, Brainbox, Pharmaceutical industry, Vaccine

RICHMOND, Va., May 4, 2023 /PRNewswire/ -- BRAINBox Solutions today announced it will report on summary demographic and clinical trends data from the HeadSMART II pivotal trial of its concussion diagnostic and prognostic test, BRAINBox TBI, at two upcoming medical conferences. The company was selected to present at podium presentations at the Society for Academic Emergency Medicine annual meeting (May 16-19 in Austin, TX), to be delivered by Damon Kuehl, MD, Vice Chair for Research in the Department of Emergency Medicine for Carilion Clinic, Vice Chair of the Virginia Tech Carilion School of Medicine's Department of Emergency Medicine, and BRAINBox Scientific Advisory Board (SAB) member; and at the 13th Annual Traumatic Brain Injury Conference, (June 19-20, Washington, DC), to be delivered by W. Franklin Peacock MD FACEP, Principal Investigator, and Professor of Emergency Medicine, Vice Chair for Research in the Department of Emergency Medicine at Baylor College of Medicine, and also a BRAINBox SAB member.

Key Points: 
  • RICHMOND, Va., May 4, 2023 /PRNewswire/ -- BRAINBox Solutions today announced it will report on summary demographic and clinical trends data from the HeadSMART II pivotal trial of its concussion diagnostic and prognostic test, BRAINBox TBI, at two upcoming medical conferences.
  • "We are now convinced that this objective test has the potential to change clinical practice.
  • The company recently commenced enrollment in an NIH-supported, multi-center clinical trial in geriatric patients and is currently completing initial pilot clinical trial in pediatric subjects (18 years of age or younger).
  • The clinical study sites were selected to reflect real world practice and include Level I Trauma Centers, Emergency Departments and Urgent Care settings in systems and community-based hospitals.